Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Kanerva, Anna ^a,b   Lavilla Alonso, Sergio ^a,b   Raki, Mari ^a,b   Kangasniemi, Lotta ^a,b   Bauerschmitz, Gerd J ^a,b,c   Takayama, Koichi ^d   Ristimäki, Ari ^b   Desmond, Renee A ^e   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d KYUSHU UNIVERSITY   (Japan)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DEXAMETHASONE; ONCOLYTIC ADENOVIRUS; SALICYLATE SODIUM; SALICYLIC ACID; VASCULOTROPIN; ONCOLYTIC VIRUS; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; SYSTEMIC THERAPY; UTERINE CERVIX CANCER; VIRUS INFECTIVITY; VIRUS REPLICATION; ADENOVIRUS; CELL DIVISION; GENETICS; HELA CELL; METABOLISM; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY;

ADENOVIRIDAE;

ADENOVIRIDAE; CELL DIVISION; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FEMALE; HELA CELLS; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION;

EID: 51449104765     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002917     Document Type: Article

References (56)

1. zur Hausen H (2002) Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2: 342-350.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-130.
3. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
4. Russell WC (2000) Update on adenovirus and its vectors. J Gen Virol 81: 2573-2604.
5. Kirn D, Martuza RL, Zwiebel J (2001) Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787.
6. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, et al. (2000) a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885.
7. Yu W, Fang H (2007) Clinical trials with oncolytic adenovirus in china. Curr Cancer Drug Targets 7: 141-148.
8. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, et al. (2006) A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107-117.
9. Kanerva A, Raki M, Hemminki A (2007) Gene therapy of gynaecological diseases. Expert Opin Biol Ther 7: 1347-1361.
10. Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, et al. (1998) Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the egr-1 promoter: Activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 9: 1409-1417.
11. Binley K, Askham Z, Martin L, Spearman H, Day D, et al. (2003) Hypoxiamediated tumour targeting. Gene Ther 10: 540-549.
12. Fechner H, Wang X, Srour M, Siemetzki U, Seltmann H, et al. (2003) A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. Gene Ther 10: 1680-1690.
13. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, et al. (1999) Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A 96: 5292-5297.
14. Cao Y, Prescott SM (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286.
15. Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, et al. (2001) Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 7: 2496-2504.
16. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT (2001) Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 3: 385-394.
17. Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, et al. (2003) The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 5: 300-310.
18. Nagi P, Vickers SM, Davydova J, Adachi Y, Takayama K, et al. (2003) Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement. J Gastrointest Surg 7: 364-371.
19. Rein DT, Breidenbach M, Nettelbeck DM, Kawakami Y, Siegal GP, et al. (2004) Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med 6: 1281-1289.
20. Wesseling JG, Yamamoto M, Adachi Y, Bosma PJ, van Wijland M, et al. (2001) Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. Cancer Gene Ther 8: 990-996.
21. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
22. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schafer G, et al. (2003) Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63: 1083-1092.
23. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L (2003) IL-1beta-mediated upregulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17: 2115-2117.
24. Lam JT, Kanerva A, Bauerschmitz GJ, Takayama K, Suzuki K, et al. (2004) Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J Gene Med 6: 1333-1342.
25. Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, et al. (2002) Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20: 973-981.
26. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, et al. (2001) Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7: 429-434.
27. Cheng WF, Chen CA, Lee CN, Chen TM, Hsieh FJ, et al. (1999) Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 93: 761-765.
28. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T (1999) Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer 80: 827-833.
29. Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, et al. (2000) Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 83: 620-625.
30. Tordjman C, Coge F, Andre N, Rique H, Spedding M, et al. (1995) Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro; interactions of non steroidal anti-inflammatory drugs with COX2. Biochim Biophys Acta 1256: 249-256.
31. Ristimaki A, Narko K, Hla T (1996) Down-regulation of cytokine-induced cyclooxygenase-2 transcript isoforms by dexamethasone: Evidence for post-transcriptional regulation. Biochem J 318: 325-331.
32. Pruzanski W, Stefanski E, Vadas P, Kennedy BP, van den Bosch H (1998) Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors. Biochim Biophys Acta 1403: 47-56.
33. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, et al. (2001) A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7: 120-126.
34. Kanerva A, Hemminki A (2004) Modified adenoviruses for cancer gene therapy. Int J Cancer 110: 475-480.
35. Bauerschmitz GJ, Kanerva A, Wang M, Herrmann I, Shaw DR, et al. (2004) Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int J Cancer 111: 303-309.
36. Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, et al. (2002) Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 62: 1266-1270.
37. Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, et al. (2004) A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther 11: 552-559.
38. Baker AH, Mcvey JH, Waddington SN, Di Paolo NC, Shayakhmetov DM (2007) The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther 15: 1410-1416.
39. Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, et al. (2007) Treatment of prostate cancer with Ad5/3Delta24hCG allows noninvasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther 6(2): 742-751.
40. Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, et al. (1997) Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study. Hum Pathol 28: 698-703.
41. Bruning A, Kohler T, Quist S, Wang-Gohrke S, Moebus VJ, et al. (2001) Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphavbeta3. Hum Gene Ther 12: 391-399.
42. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, et al. (2003) Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 63: 847-853.
43. Moriuchi M, Inoue H, Moriuchi H (2001) Reciprocal interactions between human T-lymphotropic virus type 1 and prostaglandins: Implications for viral transmission. J Virol 75: 192-198.
44. Symensma TL, Martinez-Guzman D, Jia Q, Bortz E, Wu TT, et al. (2003) COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression. J Virol 77: 12753-12763.
45. Sarkioja M, Hakkarainen T, Eriksson M, Ristimaki A, Desmond RA, et al. (2008) The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 39-untranslated region destabilization element can increase specificity. J Gene Med 10: 744-753.
46. Blair GE, Dixon SC, Griffiths SA, Zajdel ME (1989) Restricted replication of human adenovirus type 5 in mouse cell lines. Virus Res 14: 339-346.
47. Eibl G, Takata Y, Boros LG, Liu J, Okada Y, et al. (2005) Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 65: 982-990.
48. Hitt MM, Graham FL (1990) Adenovirus E1A under the control of heterologous promoters: Wide variation in E1A expression levels has little effect on virus replication. Virology 179: 667-678.
49. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, et al. (2005) Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 12: 1198-1205.
50. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, et al. (1999) Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. american society of clinical oncology. J Clin Oncol 17: 2971-2994.
51. Insel PA (1996) Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. The pharmacological basis of therapeutics. New York, NY: McGraw-Hill. pp 617-657.
52. Walsh D, Avashia J (1992) Glucocorticoids in clinical oncology. Cleve Clin J Med 59: 505-515.
53. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT (2001) Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 75: 4176-4183.
54. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, et al. (2002) Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8: 275-280.
55. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, et al. (1998) An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72: 9706-9713.
56. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, et al. (2003) Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125: 1203-1218.